| MRK |
Report |
Total revenue |
BEAT |
pred ~$16.6B vs. cons $16.33B |
MEDIUM |
| MRK |
Report |
Keytruda revenue |
BEAT |
pred ~$8.5B vs. cons ~$8.35B |
MEDIUM |
| MRK |
Report |
Gardasil/Gardasil 9 revenue |
MISS |
pred ~$0.90B vs. cons ~$1.02B |
MEDIUM |
| MRK |
Guide |
FY26 revenue guidance |
BETTER |
guide ~$66.5–67.5B vs. cons ~$66.5B (FY26) |
MEDIUM |
| MRK |
Guide |
FY26 non-GAAP EPS (underlying, ex one-time BD charges) |
BETTER |
guide ~$5.15–5.30 ex-charges vs. cons ~$5.10 (FY26); reported cut ~$2.47 for Terns |
LOW |
| MRK |
Guide |
WINREVAIR trajectory / H2 launch cadence commentary |
BETTER |
pred Q2 WINREVAIR ~$620M vs. cons ~$580M (2026Q2) |
LOW |
| MRK |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| MRK |
Return |
5-day cumulative residual |
+0.5% (FADE) |
A revenue beat + FX-aided guide raise plus Keytruda durability should drive a modest day-1 pop, but the ~20% YTD run-up has reset the bar. Out-period math is a headwind: management pre-flagged a ~$250M Q3 Keytruda wholesaler-timing reversal and Gardasil China weakness caps upside revisions, so the initial gain fades as the Street trims 2H numbers even after the beat. |
MEDIUM |